A389030 Stock Overview
A bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GENINUS Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,325.00 |
| 52 Week High | ₩2,810.00 |
| 52 Week Low | ₩1,209.00 |
| Beta | 0.58 |
| 11 Month Change | -11.49% |
| 3 Month Change | -6.69% |
| 1 Year Change | -49.43% |
| 33 Year Change | -68.70% |
| 5 Year Change | n/a |
| Change since IPO | -70.34% |
Recent News & Updates
Is GENINUS (KOSDAQ:389030) A Risky Investment?
Aug 07
Is GENINUS (KOSDAQ:389030) In A Good Position To Invest In Growth?
Apr 12Shareholder Returns
| A389030 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.3% | -4.2% | 1.9% |
| 1Y | -49.4% | 19.5% | -2.6% |
Return vs Industry: A389030 underperformed the KR Biotechs industry which returned 19.5% over the past year.
Return vs Market: A389030 underperformed the KR Market which returned -2.6% over the past year.
Price Volatility
| A389030 volatility | |
|---|---|
| A389030 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A389030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A389030's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 81 | Woongyang Park | kr-geninus.com |
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; and OncoSTATION, an automated clinical genome information analysis solution.
GENINUS Inc. Fundamentals Summary
| A389030 fundamental statistics | |
|---|---|
| Market cap | ₩44.72b |
| Earnings (TTM) | -₩12.65b |
| Revenue (TTM) | ₩6.40b |
6.9x
P/S Ratio-3.5x
P/E RatioIs A389030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A389030 income statement (TTM) | |
|---|---|
| Revenue | ₩6.40b |
| Cost of Revenue | ₩7.02b |
| Gross Profit | -₩615.03m |
| Other Expenses | ₩12.04b |
| Earnings | -₩12.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -379.37 |
| Gross Margin | -9.60% |
| Net Profit Margin | -197.59% |
| Debt/Equity Ratio | 15.6% |
How did A389030 perform over the long term?
See historical performance and comparison